December 15, 2017 / 12:15 PM / a year ago

FDA allows Alnylam to restart hemophilia treatment trials

Dec 15 (Reuters) - The U.S. Food and Drug Administration has allowed Alnylam Pharmaceuticals Inc to restart clinical tests on a drug to treat patients with a rare bleeding disorder, the company said on Friday.

Alnylam had in September stop testing the drug, fitusiran, to treat hemophilia after a patient died.

The company said the FDA decision pertained to a mid-stage study and late-stage program for fitusiran. (Reporting by Manas Mishra in Bengaluru; Editing by Savio D’Souza)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below